Immune cell study may unlock clues to better allergy eye treatments
NCT ID NCT07171307
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study examines immune cells in 60 people with allergic conjunctivitis, both those receiving desensitization therapy and those not, plus healthy controls. Researchers will analyze blood and tear samples to measure specific immune markers and cell activity. The goal is to find biological clues that could lead to improved treatments for this common eye allergy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could identify immune markers that help predict treatment response and guide future therapies for allergic conjunctivitis.
- What could go wrong
- This is an observational study, not a treatment trial. It is small (60 participants) and early, so findings may not lead to direct clinical changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONJUNCTIVITIS, ALLERGIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Instituto de Oftalmología FAP Conde de Valenciana, IAP Sede Centro
Mexico City, Mexico City, 06800, Mexico
More trials for these conditions
Other studies related to the condition(s) this trial covers.